This conference has been withdrawn from the 2021 conference schedule.
Since the beginning of the pandemic, the GRC Board of Trustees and staff have been assessing the impacts of COVID-19 on our 2021 conference season. As always, our priority is to support and preserve our conference communities and their health and safety while continuing GRC's 90-year tradition of advancing the frontiers of science. In light of the uncertainties surrounding the pandemic, the GRC Board of Trustees surveyed your conference chair(s) to determine their preference to postpone the meeting to 2022 or reschedule to a date later in the 2021 season. Per the chair's request, the Board has deferred the meeting and removed it from the 2021 schedule. Thank you for your understanding, and we hope you will be able to attend this conference in 2022.
Over 422 million people are living with diabetes with one in three adults having a lifetime risk of developing diabetes or pre-diabetes. The major costs of diabetes relate to its complications, including blindness, amputations, heart attacks and strokes, kidney failure and premature mortality.
Diabetes is a multi-system disease due to complex interactions amongst, albeit not limited to, genetic, perinatal, environmental, lifestyle and dietary factors. The phenotypic heterogeneity points to perturbation of interconnecting biological pathways, which can be modified by early intervention and optimization of internal milieu, as exemplified by the legacy effects of good glycemic control on long term outcomes in prediabetes, type 1 and type 2 diabetes.
Epigenetic modification is an important regulatory mechanism for the temporal and spatial control of gene activity which store, retain, and recall past experiences for shaping present and future behaviors, the so called "cellular memory". The recent advances in technologies have generated big multiomic datasets from clinical and experimental studies, which provide a powerful resource for discovery of new biology of complex disease such as diabetes and cardiovascular-renal disease. In pursuit of this transformational knowledge, new methodologies are needed to create, integrate and translate multi-level evidence into tools and strategies for altering disease trajectories and improving clinical outcomes.
Based on the success of our inaugural meeting in 2018, in this edition of the Gordon Research Conference, we have invited global leaders in the field of clinical, basic, data and pharmaceutical science to deliberate on the linking role of epigenetics in diabetes and its related traits and complications. Through these deliberations, we aim to highlight the interdisciplinary nature in our pursuit of using human data to discover new medicine and technologies for unmet needs. Finally, we welcome young scientists from different disciplines to submit abstracts to the associated Gordon Research Seminar (GRS) and share their work with these thought leaders and foster collaborations to advance our knowledge in the field of epigenetics and/or diabetes and complex diseases.